全文获取类型
收费全文 | 10817篇 |
免费 | 895篇 |
国内免费 | 16篇 |
专业分类
耳鼻咽喉 | 153篇 |
儿科学 | 221篇 |
妇产科学 | 183篇 |
基础医学 | 1374篇 |
口腔科学 | 215篇 |
临床医学 | 995篇 |
内科学 | 2213篇 |
皮肤病学 | 97篇 |
神经病学 | 999篇 |
特种医学 | 328篇 |
外科学 | 1696篇 |
综合类 | 354篇 |
一般理论 | 10篇 |
预防医学 | 1094篇 |
眼科学 | 219篇 |
药学 | 933篇 |
1篇 | |
中国医学 | 9篇 |
肿瘤学 | 634篇 |
出版年
2022年 | 70篇 |
2021年 | 158篇 |
2020年 | 97篇 |
2019年 | 149篇 |
2018年 | 208篇 |
2017年 | 157篇 |
2016年 | 150篇 |
2015年 | 190篇 |
2014年 | 289篇 |
2013年 | 465篇 |
2012年 | 666篇 |
2011年 | 682篇 |
2010年 | 412篇 |
2009年 | 411篇 |
2008年 | 783篇 |
2007年 | 834篇 |
2006年 | 810篇 |
2005年 | 758篇 |
2004年 | 785篇 |
2003年 | 672篇 |
2002年 | 674篇 |
2001年 | 125篇 |
2000年 | 63篇 |
1999年 | 123篇 |
1998年 | 136篇 |
1997年 | 137篇 |
1996年 | 121篇 |
1995年 | 105篇 |
1994年 | 99篇 |
1993年 | 72篇 |
1992年 | 67篇 |
1991年 | 62篇 |
1990年 | 49篇 |
1989年 | 68篇 |
1988年 | 54篇 |
1987年 | 52篇 |
1986年 | 62篇 |
1985年 | 66篇 |
1984年 | 66篇 |
1983年 | 77篇 |
1982年 | 93篇 |
1981年 | 84篇 |
1980年 | 65篇 |
1979年 | 42篇 |
1978年 | 53篇 |
1977年 | 32篇 |
1976年 | 48篇 |
1975年 | 33篇 |
1974年 | 29篇 |
1973年 | 41篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Julia H. Vermylen Gordon J. Wood Elaine R. Cohen Jeffrey H. Barsuk William C. McGaghie Diane B. Wayne 《Journal of pain and symptom management》2019,57(3):682-687
Introduction
Physician communication impacts patient outcomes. However, communication skills, especially around difficult conversations, remain suboptimal, and there is no clear way to determine the validity of entrustment decisions. The aims of this study were to 1) describe the development of a simulation-based mastery learning (SBML) curriculum for breaking bad news (BBN) conversation skills and 2) set a defensible minimum passing standard (MPS) to ensure uniform skill acquisition among learners.Innovation
An SBML BBN curriculum was developed for fourth-year medical students. An assessment tool was created to evaluate the acquisition of skills involved in a BBN conversation. Pilot testing was completed to confirm improvement in skill acquisition and set the MPS.Outcomes
A BBN assessment tool containing a 15-item checklist and six scaled items was developed. Students' checklist performance improved significantly at post-test compared to baseline (mean 65.33%, SD = 12.09% vs mean 88.67%, SD = 9.45%, P < 0.001). Students were also significantly more likely to have at least a score of 4 (on a five-point scale) for the six scaled questions at post-test. The MPS was set at 80%, requiring a score of 12 items on the checklist and at least 4 of 5 for each scaled item. Using the MPS, 30% of students would require additional training after post-testing.Comments
We developed a SBML curriculum with a comprehensive assessment of BBN skills and a defensible competency standard. Future efforts will expand the mastery model to larger cohorts and assess the impact of rigorous education on patient care outcomes. 相似文献2.
3.
4.
5.
This review discusses treatment options for men with premature ejaculation (PE), a common sexual dysfunction characterized
by short ejaculatory latency, decreased sexual satisfaction, and distress. For a number of reasons, including embarrassment
and the belief that PE is a normal part of aging, that it has no effective treatment, or that it will resolve itself, few
men with PE seek treatment. Although several treatment options exist (eg, behavioral, cognitive, and sex therapy methods;
desensitizing drugs; off-label use of antidepressants, phosphodiesterase type 5 inhibitors, or à-blockers), the majority of
men with PE are not satisfied with their results. New pharmacologic drugs develped specifically for the treatment of PE are
undergoing evaluation in clinical trials. For example, recent clinical research studies have revealed on-demand administration
of one such drug, dapoxetine, which achieved significant improvements in ejaculatory latency, control over ejaculation, and
satisfaction with sexual intercourse. In addition, partners of men who received dapoxetine likewise reported improved satisfaction
with sexual intercourse. Future studies may reveal that integration of pharmacologic drugs with psychologic and/or behavioral
therapy techniques may be the optimal approach to the management of PE. PE is a treatable condition, and new drugs in development
may provide benefits over those available. 相似文献
6.
7.
8.
9.
Najat C Daw Wayne L Furman Clinton F Stewart Lisa C Iacono Mark Krailo Mark L Bernstein Janet E Dancey Rose Anne Speights Susan M Blaney James M Croop Gregory H Reaman Peter C Adamson 《Journal of clinical oncology》2005,23(25):6172-6180
PURPOSE: Epidermal growth factor receptor is expressed in pediatric malignant solid tumors. We conducted a phase I trial of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in children with refractory solid tumors. PATIENTS AND METHODS: Gefitinib (150, 300, 400, or 500 mg/m2) was administered orally to cohorts of three to six patients once daily continuously until disease progression or significant toxicity. Pharmacokinetic studies were performed during course one (day 1 through 28). RESULTS: Of the 25 enrolled patients, 19 (median age, 15 years) were fully evaluable for toxicity and received 54 courses. Dose-limiting toxicity was rash in two patients treated with 500 mg/m2 and elevated ALT and AST in one patient treated with 400 mg/m2. The maximum-tolerated dose was 400 mg/m2/d. The most frequent non-dose-limiting toxicities were grade 1 or 2 dry skin, anemia, diarrhea, nausea, and vomiting. One patient with Ewing's sarcoma had a partial response. Disease stabilized for 8 to > or = 60 weeks in two patients with Wilms' tumor and two with brainstem glioma (one exophytic). At 400 mg/m2, the median peak gefitinib plasma concentration was 2.2 microg/mL (range, 1.2 to 3.6 microg/mL) and occurred at a median of 2.3 hours (range, 2.0 to 8.3 hours) after drug administration. The median apparent clearance and median half-life were 14.8 L/h/m2 (range, 3.8 to 24.8 L/h/m2) and 11.7 hours (range, 5.6 to 22.8 hours), respectively. Gefitinib systemic exposures were comparable with those associated with antitumor activity in adults. CONCLUSION: Oral gefitinib is well tolerated in children. Development of the drug in combination with cytotoxic chemotherapy will be pursued. 相似文献
10.